Marizyme, Inc. · OTC:MRZM
Marizyme — 2021 BIOTECH Showcase at J.P. Morgan Healthcare Conference Week
35 slides from Marizyme's conference presentation, Feb 26, 2021
Slide 1: Marizyme Corporate Overview
January 2021 Marizyme® Corporate Overview Dr. Neil J. Campbell President & CEO ncampbell@marizyme.com See eee @ marzyme
Slide 2: Safe Harbor Statements
Safe Harbor Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers are cautioned not to place undue reliance on these forward-looking sta
Slide 3: Today's Marizyme Presentation
Today’s Marizyme® Presentation * Company Overview * Value Proposition ™ * Science & Technology g\ * Clinical Studies @ * Commercialization OTCQB:MRZM * Management * Summary © 3 @ marizyme
Slide 4: Company Overview
Company Overview 2021 BIOTECH Showcase at J.P. Morgan Healthcare Conference Week January 2021 4 @ marizyme
Slide 5: Marizyme Overview
Marizyme Overview « Marizyme is an integrated life sciences company dedicated to the acquisition, development and commercialization of therapies, devices and related products that protect and enhance cellular functions. * The Company's flagship product DuraGraft®, is an intra-operative vascular graf
Slide 6: Marizyme's Current Structure — January 2021
Marizyme’s Current Structure — January 2021 Building a business in cellular and tissue-based protection through devices and therapeutics. Marizyme © Corporate Somahtution, Marizyme Inc. Sciences, Inc. “SOMA” “msi” 6 @ marizyme
Slide 7: Value Proposition
Value Proposition 2021 BIOTECH Showcase at J.P. Morgan Healthcare Conference Week January 2021 7 @ marizyme
Slide 8: Cellular Health
Cellular Healt Targeting the cell and tissues in disorders and diseases will drive new product revenues Maintain Cell Viability Protect Cell Function Protect Cell Function Maintain Cell Structural Integrity Proper Tissue Architecture and Function Maintain Proper Tissue Architecture and Function Uniq
Slide 9: Science & Technology
Science & Technology 2021 BIOTECH Showcase at J.P. Morgan Healthcare Conference Week January 2021 9 @ marizyme
Slide 10: Endothelial Cells
Endothelial Cells Microenvironment Supports the function and structural integrity of the endothelium Maintains the homeostasis of the tissue microenvironment ex vivo Organ and Tissue Specific Cells Supports and maintains organ and tissue structure and function 10 @ marizyme
Slide 11: Marizyme's Soma Technology Platform
Marizyme’s Soma™ Technology Platform Maintaining cellular viability, integrity, and protection from cell death cascades Supports cellular viability, integrity, structure, and function Cellular and tissue-specific J preservation j/ | Maintains proper tissue architecture and function T4 Preserves orga
Slide 12: Coronary Artery Bypass Grafting - CABG
Coronary Artery Bypass Grafting - CABG Potential: 90% of CABG procedures WW use free saphenous vein and free arterial grafts (for which DuraGraft® is indicated)". * Coronary Artery Bypass Grafting (CABG) involves the construction of an alternative conduit to bypass a narrowed or occluded coronary ar
Slide 13: Intraoperative Endothelial Damage and Graft Disease
Intraoperative Endothelial Damage and Graft Disease Undamaged endothelium Within Minutes to Hours past-grafting Platelets, inflammatory cells and thrombi appear at sites of injury Endothelial cell damage occurs | Within days to Weeks Medial smooth muscle cells proliferate, wall thickening matrix thi
Slide 14: DuraGraft - Endothelial Damage, Graft Failure, & Adverse Outcomes
DuraGraft - Endothelial Damage, Graft Failure, & Adverse Outcomes CABG - The Problem Clinical Impact of Graft Disease and Failure iC) Angina e Myocardial infarction e Repeat Revascularization CC) Re-admission iC) Poorer Quality of Life 14 @ marizyme
Slide 15: DuraGraft Studies
DuraGraft® Studies 2021 BIOTECH Showcase at J.P. Morgan Healthcare Conference Week January 2021 15 @ marizyme
Slide 16: DuraGraft Prevents Endothelial Cell Death
OHours __DuraGraft Buffered Standard of care causes cell death almost immediately Endothelial cells die within minutes g Green fluorescence indicates viable cells DuraGraft prevents cell death, damage and = Ret orescenes neater deat oot ‘ minis ae - Endothelial Cells dysfunction, preventing ischemic
Slide 17: DuraGraft Precursor Clinical Data — VA Boston Healthcare
raGraft Precursor) Clinical Data 1 — VA Boston Healthcare U.S. Retrospective Study 2,436 CABG Patients + DuraGraft Treatment vs Standard of Care Sequential Historical Cohort Study Significant reductions in long-term clinical events with DuraGraft (up to 15 years) Reduction in Myocardial Infarction R
Slide 18: Prospective Randomized Study: Use of DuraGraft in CABG Patients
Prospective Randomized Study: Use of DuraGraft in CABG Patients Randomized Study to Evaluate the Use of DuraGraft® in Patients Undergoing CABG Louis P. Perrault, MD, Ph.D., FRCSC, FACS, Montreal Heart Institute, University of Montreal Prospective, Randomized, Double-blind, Comparative (within-patien
Slide 19: Prospective Randomized Study: Primary Objectives
Prospective Randomized Study: Primary ectives A within-patient randomized, double-blind study to compare the impact of a DuraGraft treated graft, against a Standard of Care treated graft. 125 Patients CABG 2 Veins ¢ Short-Term Structural Changes (3-months) * Change in the mean wall thickness of pair
Slide 20: Prospective Randomized Study: Results Lumen Narrowing
Prospective domized Study: Resul men Narrowin DuraGraft Group Demonstrates Reduction in Maximal (Focal) Lumen Narrowing in mITT Population Disease progression is more Pronounced in the Proximal segment Maximal (Focal) Lumen Narrowing - Whole Graft {(TVD-LD)/TVD} Maximal (Focal) Lumen Narrowing - Pro
Slide 21: Prospective Randomized Study: Adverse Events
Prospective Randomized Study: Adverse Events Safety: Adjudicated AEs - mITT Population 0-3 Months 3-12 Months fvents | ttos [Pets | nczso [Pvatel] Even nor [near | netos | vee sv Occlusion 10 (8.0%) | 9(7.2%) | 19(7.6%)] 0.80 |}svG Occlusion 1.0%) | 0 | 1(05%) | 0.32 Mace ° ° ° nfa_||mace az0%) | 0
Slide 22: Commercialization
Commercialization 2021 BIOTECH Showcase at J.P. Morgan Healthcare Conference Week January 2021 22 @ marizyme
Slide 23: Marizyme's Commercial Approach
Marizyme’s Commercial Approach Two platform technologies afford multiple opportunities for commercialization and revenue. Develop Organically & Sell e Organic Revenue Seek Various Types of Drive Commercialization Strategic Partnerships in Large/Tough Markets Monetize Opportunistically Marizyme Core
Slide 24: CABG - The Problem, DuraGraft Preservation Solution
CABG -— The Problem DuraGraft Preservation Solution Clinical Impact of Graft a 4 DuraGraft preservation solution plays an important role in Disease and Failure a eed i preventing intraoperative endothelial damage and Ischemia Reperfusion Injury C) Repeat Revascularization DuraGraft Preservation Solu
Slide 25: DuraGraft intraoperative vascular graft treatment
Potential: 90% of CABG procedures WW use free saphenous and free arterial grafts (for which DuraGraft® is indicated)’. + DuraGraft is an intraoperative vascular graft treatment that maintains endothelial function and structure, reducing the incidence and complications associated with graft failure f
Slide 26: DuraGraft is emerging as the new standard of care for CABG Globally
DuraGratt is emerging as the new standard of care for CABG Globally Limitations of Saline, Blood & Buffered Solutions Satin blood and buffered solutions are not preservation solutions and DO NOT protect against DuraGraft _ The World's 1* Endothelial Damage Inhibitor hana TF ee fee WY v Does Not Acti
Slide 27: Approved, Pending and Targeted Countries
APPROVED: EU Member countries UK Switzerland Malaysia Singapore Hong Kong India Philippines. Turkey PENDING: US Australia New Zealand S. Africa Norway TARGETED: Chile Argentina Colombia Uruguay Ecuador Peru Vietnam Indonesia Lebanon Israel Jordan Iran Saudi Arabia UAE Canada Mexico 27 @ marizyme
Slide 28: Management
Management 2021 BIOTECH Showcase at J.P. Morgan Healthcare Conference Week January 2021 28 @ marizyme
Slide 29: Marizyme's Leadership
Marizyme’s Leadership A successful and deeply experienced management team, board and advisors + James Sapirstein Chairman of the Board * Dr. Neil Campbell President & Chief Executive Officer + Bruce Harmon Chief Financial Officer * Roger Schaller EVP, Commercial Operations + Dr. Don Very EVP, Resear
Slide 30: Summary
Summary 2021 BIOTECH Showcase at J.P. Morgan Healthcare Conference Week January 2021 30 @ marizyme
Slide 31: Summary - Marizyme's Value Proposition
Summary - Marizyme’s Value Proposition Protecting, Maintaining, and Supporting Cellular Function Maintains Cell Viability and Metabolism During Ischemic Storage 7 7 . " - Minimizes Marizyme is an integrated life sciences Cellular Death Supports Cellular company dedicated to the acquisition, Lett pie
Slide 32: Summary - The DuraGraft Advantage in CABG
Summary - The DuraGraft® Advantage in CAB Becoming the standard of care for CABG globally in 2021 Prospective, Randomized, Multi-Center Within-Patient Study DuraGraft’ Clinical Study Summary DuraGraft has been proven to reduce both graft level negative remodeling and clinical complications sag Wal T
Slide 33: Summary - Marizyme's Commercial Approach
Summary - Marizyme’s Commercial Approach Two platform technologies afford multiple opportunities for commercialization and revenue. Develop Organically & Sell Drive Organic Revenue Seek Various Types of Drive Commercialization Strategic Partnerships in Large/Tough Markets Monetize Opportunistically
Slide 34: Summary - Marizyme Structured for Success
Summary - Marizyme Structured for Success Building a business in cellular protection and support through devices, therapeutics and diagnostics. On-market commercial stage public company * Two major science & technology platforms Corporate + Proprietary and best-in-class potential * Platforms generat
Slide 35: Thank You
@ marizyme Thank You Marizyme, Inc. 555 Heritage Drive, Suite 200 Jupiter, FL 33458 www.Marizyme.com
Marizyme — 2021 BIOTECH Showcase at J.P. Morgan Healthcare Conference Week on 6ix